Pre-hypertension Clinical Trial
— HEATOfficial title:
Heat & Aerobic Training (HEAT) for Pre-Hypertensive Middle-Aged Adults
Verified date | April 2019 |
Source | University of Illinois at Urbana-Champaign |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is intended for inactive, middle-aged adults with untreated pre-hypertension who live in the Urbana-Champaign area, who are interested in a comprehensive program designed to enhance physical activity & reduce blood pressure. All participants will be asked to engage in a program developed in accordance with American Heart Association's recommendations. Specifically, the program will encourage and support lifestyle behavior changes such as quitting smoking, eating heart-healthy food, and reducing excessive alcohol, in addition to weekly exercise. The exercise program will involve a 14-week aerobic training program (3 weekly sessions, scheduled at study participants' convenience), and 2 pre- and 2-post-testing sessions.
Status | Completed |
Enrollment | 41 |
Est. completion date | May 24, 2017 |
Est. primary completion date | May 24, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 45 Years to 64 Years |
Eligibility |
Inclusion Criteria: - Age 45 to 64 - Confirmed pre-hypertensive (120-139 mmHG Systolic / 80-89 Diastolic mmHG) blood pressure by our laboratory staff - Low active (< 2 days per week for 30+ minutes over the past 3 months) - Able and willing to try to adhere to American Heart Association guidelines for managing multiple lifestyle factors contributing to high blood pressure including increasing physical activity (at least 50 minutes, 3 times/week as part of our supervised training sessions), stopping smoking altogether, eating healthier (limiting sodium, eating fruit, veggies, low-fat dairy and lean protein, and reducing saturated fat and total fat), drinking less alcohol (1-2 drinks a day max) and achieving and maintaining a healthy bodyweight (striving or a body mass index between 18 and 25). - Able to commit to the full length of our program without missing more than 2 consecutive weeks - Capable of performing moderately intensive aerobic exercise - Willing to be randomized to one of two groups - Able to commute to and from fitness facility and UIUC campus - Own smartphone and have reliable at-home internet access - Have correctable vision (i.e., at least 20/40 with glasses or contacts with no color blindness) - Not involved in regular weekly relaxation methods (e.g., yoga, meditation) or heat therapy (e.g., steam-room, sauna, hot baths) - Not heat sensitive (e.g., have not experienced heat-induced severe rashes, pain, numbness, or tingling; experienced heat-related cramps, illness, or heatstroke; or had surgery requiring general anesthesia that has caused subsequent difficulty regulating body temperature) - Do not have any type of neuropathy (e.g., peripheral, diabetic) - Not depressed as indicated by a telephone screening (Abbreviated 5-item Geriatric Depression Scale; GDS-5 score < 2) - No cognitive impairment as indicated by a telephone screening (Telephone Interview Cognitive Survey; TICS score > 21) Exclusion Criteria: - Too young (< 45) or too old (> 64) - Normotensive (< 120 mmHG Systolic / < 80 Diastolic mmHG) or hypertensive (> 140 mmHG Systolic / > 90 Diastolic mmHG) blood pressure - Too active (as defined by regularly exercise 2 or more days per week for 30+ minutes over the past 3 months) - Unable or unwilling to comply with American Heart Association guidelines for managing multiple lifestyle factors contributing to high blood pressure including increasing physical activity (at least 50 minutes, 3 times/week as part of our supervised training sessions), stopping smoking altogether, eating healthier (limiting sodium, eating fruit, veggies, low-fat dairy and lean protein, and reducing saturated fat and total fat), drinking less alcohol (1-2 drinks a day max) and achieving and maintaining a healthy bodyweight (striving or a body mass index between 18 and 25). - Unable to commit to full length of program - Incapable of performing moderately intensive aerobic exercise - Unwilling to be randomized to one of two groups - Unable to commute to and from fitness facility and UIUC campus - Does not own smartphone or have reliable at-home internet access - Does not have correctable vision (i.e., at least 20/40 with glasses or contacts with no color blindness) - Already involved in regular weekly relaxation methods (e.g., yoga, meditation) or heat therapy (e.g., steam-room, sauna, hot baths) - Has heat sensitivity (e.g., heat-induced severe rashes, pain, numbness, or tingling; experienced heat-related cramps, illness, or heatstroke; or had surgery requiring general anesthesia that has caused subsequent difficulty regulating body temperature) - Has any type of neuropathy (e.g., peripheral, diabetic) - Has depression (as defined by GDS-5 score of 2 or higher) - Has cognitive impairment (as defined by < 21 on TICS) |
Country | Name | City | State |
---|---|---|---|
United States | Louise Freer Hall, Exercise Technology & Cognition Laboratory, Rm 253 | Urbana | Illinois |
Lead Sponsor | Collaborator |
---|---|
University of Illinois at Urbana-Champaign |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | blood flow | Participants will be asked to fast for 6 hours and avoid alcohol & caffeine for 24 hours. They will arrive in a postprandial state and blood flow will be assessed on the calf using strain-gauge plethysmography. Data will be presented as peak hyperemic calf blood flow (CBF) and total CBF. Total CBF will be calculated as area under the curve of the 3-min hyperemic CBF response, based on 13 measures (post-occlusion) using the trapezoidal integration method (see Heffernan et al 2009). Total CBF is an overall estimate of the dilatory capacity of the vessels and therefore serves as an indirect measure of endothelial function. | 14-week change | |
Primary | blood pressure | Resting systolic and diastolic will be assessed on the upper-arm with an automated Omron device that takes 3 continuous measurements and reports the average. After study enrollment, participants will be asked to avoid certain medications, foods and beverages known to alter these measurements. Upon entering the research site, participants will be instructed to sit quietly in a dimly lit room for 10 minutes prior to assessments. Staff will then assess blood pressure in three sequential positions (lying supine, sitting in chair, standing). The 14-week change in blood pressure will be defined as the difference between baseline and program end, using the average measures recorded at each position for systolic, diastolic, and mean arterial pressure. | 14-week change | |
Secondary | anxiety | Perceptions of anxiety will be measured by the Hospital Anxiety and Depression Scale (HADS). Items for each subscale (anxiety and depression) will be summed (un-weighted) and averaged. | 14-week change, intra-session change | |
Secondary | mindfulness | The 15-item Mindfulness and Attention Scale (MAAS) will be used to assess mindfulness. A composite score will be computed based on an average of the unweighted sum of items. | 14-week change | |
Secondary | stress | Perceived stress will be assessed with the 10-item Perceived Stress Scale. A composite score will be calculated based on an unweighted sum and average of the items. | 14-week change, intra-session change | |
Secondary | quality of life | Quality of life will be measured by the 5-item Satisfaction with Life Scale. Items will be summed and averaged. | 14-week change | |
Secondary | perceptions of memory | Assessed by the 50-item Memory Self-Efficacy Questionnaire and the 12-item Memory Controllability Inventory. Items for each scale and subscale will be summed (un-weighted) and averaged. Scale composites will be used individually. | 14-week change | |
Secondary | processing speed | A linear combination (composite score based on an un-weighted sum) based on performance on the Digit Symbol Coding Task, Letter Comparison and Pattern Comparison will be used as an index of cognitive processing speed. | 14-week change | |
Secondary | inhibition/attentional control | A linear combination based on performance on standard Stroop and Flanker paradigms will be used as an index of inhibitory control. Established "cognitive cost" algorithms will be used incorporating only the difference in reaction times as one progresses to the most challenging trials. Scores will be weighed evenly across tests when calculating the composite index of inhibition/attentional control. | 14-week change | |
Secondary | memory | A linear combination based on performance on the N-back and Sternberg Task (working memory) as well as Logical Memory Test, Free Recall and Paired Associates (episodic memory) will be used as an overall index of memory ability. Reaction times will be weighed evenly across tests when calculating the composite measure. Only the most challenging trials of N-Back (2-back) will be used to compute an average reaction time score. | 14-week change | |
Secondary | visual spatial skills | A linear combination based on performance on the Card Rotations Test, Hidden Patterns Test, Spatial Relations, Paper Folding, and Form Boards will be used as an index of visio-spatial skills. Reaction times will be weighed evenly across tests when calculating the composite measure. | 14-week change | |
Secondary | multi-tasking | A linear combination based on performance on a Dual Task and Task-Switching paradigm will be used as an index of multi-tasking ability. The algorithm will use established measures involving cost in reaction times. Performance on both tests will be evenly weighted. | 14-week change | |
Secondary | global executive functioning | An iPad-version of the established Trail-Making (A&B) Test will be used to assess general executive functioning overall. The iPad version involves trials with stationary and moving stimuli within the A (alpha-only) and B (alpha-numeric) condition. A modified algorithm based on the commonly used index of global executive function (subtracting B - A) will be implemented for data analysis. Specifically, the outcome measure will be calculated as: Trails AB reaction time (RT) cost = ((Average RT for hard/moving B trials) - (Average RT for easy/stationary B trials)) - ((Average RT for hard/moving A - Average RT for easy/stationary A trials)). |
14-week change |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03313284 -
Respiratory Muscle Training and Intermittent Hypoxia: Additive Health Effects?
|
N/A | |
Completed |
NCT01741779 -
Diet and Whole-body Vibration Training on Cardiovascular and Autonomic Function
|
N/A | |
Withdrawn |
NCT01074918 -
Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00288158 -
Primary Prevention of Hypertension in Obese Adolescents
|
Phase 2 | |
Completed |
NCT01190319 -
Study: Effects of Strawberries on Blood Pressure
|
N/A | |
Completed |
NCT01008176 -
Restoring Sleep Homeostasis to Lower Blood Pressure
|
N/A | |
Unknown status |
NCT02197910 -
Different Dosages of Bioactive Wheat Peptides and Blood Pressure Level and CVD Risk Biomarkers in Healthy Subjects
|
N/A | |
Recruiting |
NCT04543656 -
Personalized Blood Pressure Care Using IoMTs and Artificial Intelligence
|
N/A | |
Completed |
NCT03168789 -
Tension Tamer Randomized Control Trial
|
N/A | |
Completed |
NCT00553969 -
Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease
|
Phase 1/Phase 2 | |
Completed |
NCT00170937 -
A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome
|
Phase 4 | |
Completed |
NCT01741766 -
The Effects of Stretching Training on Arterial Function and Autonomic Control
|
N/A | |
Completed |
NCT02143817 -
Whole Body Vibration Combined With L-citrulline Supplementation on Cardiovascular Function and Body Composition
|
N/A | |
Terminated |
NCT00388388 -
Losartan Versus Hydrochlorothiazide in Reversing Remodeling of Small Arteries in Pre-Hypertensive Pre-Diabetic Subjects
|
Phase 2 | |
Completed |
NCT02148458 -
Short Term Intermittent Fasting and Mediterranean Diet
|
N/A | |
Terminated |
NCT01349114 -
Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects
|
Phase 4 | |
Completed |
NCT02038179 -
Center of Research Translation (CORT) Project 2
|
Phase 2/Phase 3 | |
Completed |
NCT00970931 -
Hypertension Prevention in Pre-Hypertensive Individuals
|
Phase 3 | |
Completed |
NCT01202175 -
Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension
|
Phase 4 | |
Not yet recruiting |
NCT01364675 -
Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive Subjects
|
N/A |